Inhibition of endotoxin response by synthetic TLR4 antagonists.
about
Lipid A modification systems in gram-negative bacteriaThe Crystal Structure of Human Soluble CD14 Reveals a Bent Solenoid with a Hydrophobic Amino-Terminal PocketDrugs to block cytokine signaling for the prevention and treatment of inflammation-induced preterm birthDifferential induction of the toll-like receptor 4-MyD88-dependent and -independent signaling pathways by endotoxins.Synthesis of serine-based glycolipids as potential TLR4 activators.Kdo2-Lipid A of Escherichia coli, a defined endotoxin that activates macrophages via TLR-4.Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies.Characterization of TRIF selectivity in the AGP class of lipid A mimetics: role of secondary lipid chains.Modulating LPS signal transduction at the LPS receptor complex with synthetic Lipid A analoguesProtective effect of ginsenosides Rg1 and Re on lipopolysaccharide-induced sepsis by competitive binding to Toll-like receptor 4Update on toll-like receptor-directed therapies for human diseaseCardiopulmonary Profile in Streptozotocin-Induced Type 1 Diabetic Rats during Systemic Endotoxemia.Discovery and development of toll-like receptor 4 (TLR4) antagonists: a new paradigm for treating sepsis and other diseases.Conformationally constrained lipid A mimetics for exploration of structural basis of TLR4/MD-2 activation by lipopolysaccharide.Free thiol group of MD-2 as the target for inhibition of the lipopolysaccharide-induced cell activationNovel pharmacologic approaches to the management of sepsis: targeting the host inflammatory response.Treadmill exercise preconditioning attenuates lung damage caused by systemic endotoxemia in type 1 diabetic rats.Toll-like receptor 4 modulation as a strategy to treat sepsis.Toll-like receptor-4 antagonist eritoran tetrasodium for severe sepsis.Prophylactic and therapeutic implications of toll-like receptor ligands.Marine compounds with therapeutic potential in gram-negative sepsis.Deactivation of the lipopolysaccharide antagonist eritoran (E5564) by high-density lipoprotein-associated apolipoproteins.Binding and Cellular Activation Studies Reveal That Toll-like Receptor 2 Can Differentially Recognize Peptidoglycan from Gram-positive and Gram-negative Bacteria.Pivotal involvement of Fcgamma receptor IIA in the neutralization of lipopolysaccharide signaling via a potent novel anti-TLR4 monoclonal antibody 15C1.Lipopolysaccharide-induced hemolysis: Evidence for direct membrane interactions.E5564 inhibits immunosuppressive cytokine IL-10 induction promoted by HIV-1 Tat proteinInhibition of corneal inflammation by the TLR4 antagonist Eritoran tetrasodium (E5564).Identification of undecaprenyl phosphate-beta-D-galactosamine in Francisella novicida and its function in lipid A modification.Exercise pretraining attenuates endotoxin-induced hemodynamic alteration in type I diabetic rats.Aminosugar-based immunomodulator lipid A: synthetic approaches.Structure and Immunological Activity of the Lipopolysaccharide Isolated from the SpeciesAlkalimonas delamerensis
P2860
Q24650951-8FD01BB8-EDB7-4989-B741-57A93F46F390Q27675591-5FFADAF8-A472-4645-8B6D-DF2D1E55350BQ28081049-13DDA1F0-6AAB-4FCA-8B22-FC73BB3051F5Q33769086-711AEA76-3B94-4AFE-8D89-DA7A6F8DB3C0Q33825150-85F853AC-BCBA-4739-9017-6ABB9D79B810Q33993559-B81788C2-652A-47E7-A651-A4EA02B60F8EQ34726541-9EC9310F-7711-4F84-84C7-A3A8F7FEEBC0Q35088222-6096F7C8-1138-4146-B20A-5ED18AD2F4EDQ35737359-E648A69B-D90A-4CB5-A118-0A6C35534983Q35960905-DCE5C4D9-84EA-4E7B-A131-121DD21300A6Q36171745-FF9FC495-A7CB-4113-BC0C-5B3D6FCFDEFBQ36825626-488B8786-7041-4152-B560-259CA8C293F7Q37169130-4FF076A4-2D40-4356-A1BB-11446F43E0FEQ37323250-E04A999E-2BEB-4232-B524-57D80EFEBBD0Q37339321-D5FC4816-10A9-4D4C-B58B-50009500682CQ37367885-9B05AF64-7FEB-43DA-89B2-D8130B03E6DAQ37413309-3BE7DB27-79FE-46D9-9108-A5FD82D86E9DQ37731959-F6E12910-CA13-4CA3-A089-5E6C24DDDA91Q37879190-370ECF05-ED72-404F-8C36-EE696DA3D250Q37989884-B16A98DA-ECF5-41EC-A210-AB3D3A63BF2FQ38115689-FF8DFADA-4EDC-433F-87A3-C0906A0FFBC3Q38336848-AD5B0002-71CE-4EE5-9BEB-A0177A739E1DQ39891823-DAD800ED-5A4A-4D8D-880F-066D85C56136Q40070971-1A2DDE10-7217-4537-A2EE-A06BC9DCFD41Q41497368-CED2A73A-433B-4A2C-A512-9FE32D5E89B6Q41620362-D85712D8-6765-4690-A9CF-ED7B27C25BB1Q41905068-7D651E2E-FB7D-4F6F-B2F2-E5D3B4B1FBA1Q43106542-69C762D6-EFFF-4B5F-BAA8-B5CFB796F214Q46314577-4038CD06-C6EB-423F-96A5-2A0CBFF6E4ECQ49592130-49043EAC-9ADB-4CAA-BF49-F6E5C25D2EB5Q57630119-3D88CEF5-4389-4A73-8AAC-7890775BA07F
P2860
Inhibition of endotoxin response by synthetic TLR4 antagonists.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Inhibition of endotoxin response by synthetic TLR4 antagonists.
@ast
Inhibition of endotoxin response by synthetic TLR4 antagonists.
@en
type
label
Inhibition of endotoxin response by synthetic TLR4 antagonists.
@ast
Inhibition of endotoxin response by synthetic TLR4 antagonists.
@en
prefLabel
Inhibition of endotoxin response by synthetic TLR4 antagonists.
@ast
Inhibition of endotoxin response by synthetic TLR4 antagonists.
@en
P2093
P356
P1476
Inhibition of endotoxin response by synthetic TLR4 antagonists.
@en
P2093
Daniel P Rossignol
Lynn D Hawkins
William J Christ
P304
P356
10.2174/1568026043388123
P577
2004-01-01T00:00:00Z